Clinical trial · Interventional
Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)
Phase II Study of Nanocurcumin Versus Placebo for Patients Undergoing Radiotherapy for Prostate Cancer
NCT02724618CI-TRIAL-00029891unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curcumin | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
| RT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Curcumin plus RT
- description
- 120mg/day nanocurcumin during RT course
- interventionNames
- Drug: Curcumin
- Radiation: RT
- type
- PLACEBO_COMPARATOR
- label
- Placebo plus RT
- description
- 120mg/day placebo of nanocurcumin during RT course
- interventionNames
- Radiation: RT
- Drug: Placebo
Primary outcomes (1)
- measure
- Proctitis [assessed using Common terminology criteria for adverse events (CTCAE)]
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate * Candidate for External Beam Radiotherapy * ECOG performance status 0-2 Exclusion Criteria: * Patients with Metastatic Prostate Cancer * Patients with Kidney \& Liver dysfunction * Gastrointestinal disorders such as IBD, reflux and peptic ulcers * Any adverse reaction to curcumin
References
Publications (0)
Data not yet available
No reference posted for this study.